ClinicalTrials.Veeva

Menu

Cerebral Atherosclerosis Research With Positron Emission Tomography (CARPET)

Seoul National University logo

Seoul National University

Status

Invitation-only

Conditions

Cerebral Infarction

Treatments

Diagnostic Test: FDG-PET

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

  • Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
  • Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.

Participants will:

  • Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
  • Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
  • Maintain regular clinic visits for up to 24 months following the index stroke

Enrollment

310 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • acute ischemic stroke patients who admitted within seven days after symptom onset

Exclusion criteria

  • Patients with unstable vital signs or neurological symptoms
  • Patients with estimated glomerular filtration rate less than 30ml/min
  • Patients with uncontrolled diabetes requiring persistent insulin injection
  • During pregnancy or while breastfeeding
  • Patients with impaired consent capacity
  • Patients with diagnosed/treatment for dementia
  • Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems